Supportive Care for Lung Cancer
Trial Summary
What is the purpose of this trial?
This phase II trial tests whether a supportive care intervention (Resiliency among Older Adults Receiving Lung Cancer Treatment \[ROAR-LCT\]) is effective in improving physical and emotional wellbeing in patients with stage IIIA, IIIB, and IV lung cancer undergoing cancer treatment. Lung cancers are one of the most common cancers. Lung cancers occur in the chest and often cause symptoms for patients. Poor physical performance and negative mood are two risk factors for a decline in functional status. Targeted interventions may address these two risk factors and improve functional status and resilience. Physical therapy and relaxation interventions (i.e. progressive muscle relaxation) are two such interventions that may improve symptoms and quality of life for patients with cancer.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It seems likely that you can continue them, as there are no specific exclusions related to medications.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on supportive care interventions like physical therapy and relaxation, so it's likely you can continue your current treatments, but you should confirm with the trial coordinators.
What data supports the idea that Supportive Care for Lung Cancer is an effective treatment?
The available research shows that Supportive Care for Lung Cancer, which includes exercise and physical therapy, is effective in improving the quality of life for patients. One study found that patients who participated in pulmonary rehabilitation experienced less difficulty breathing and improved mobility compared to those who did not. Another study highlighted that this type of care can enhance exercise tolerance and overall health-related quality of life. Additionally, a review of various studies confirmed that pulmonary rehabilitation helps improve lung function and physical activity levels, making it a beneficial treatment for lung cancer patients.12345
What data supports the effectiveness of the treatment for lung cancer?
Research shows that pulmonary rehabilitation, which includes exercise and physical therapy, can improve exercise capacity, reduce breathing difficulties, and enhance quality of life for lung cancer patients. These benefits are seen both during and after cancer treatment, suggesting that similar supportive care interventions could be effective.12345
What safety data exists for supportive care treatments in lung cancer?
The safety of supportive care treatments, such as exercise interventions, for lung cancer patients is generally supported by existing research. Studies indicate that exercise-based interventions, including prehabilitation and pulmonary rehabilitation, are safe and can improve physical and psychological health. Prehabilitation, in particular, is noted to be a safe intervention without side effects, although its impact on reducing postoperative complications and mortality is still under discussion. Overall, these interventions are considered safe and beneficial, especially for high-risk patients with impaired lung function.56789
Is supportive care for lung cancer, including exercise and rehabilitation programs, safe for humans?
Is pulmonary rehabilitation a promising treatment for lung cancer?
Yes, pulmonary rehabilitation is a promising treatment for lung cancer. It helps improve exercise tolerance, quality of life, and surgical readiness. It also reduces complications from surgery and allows patients to be more active, enhancing their ability to participate in family life and manage their condition better.510111213
How is pulmonary rehabilitation different from other treatments for lung cancer?
Pulmonary rehabilitation is unique because it is a non-medication treatment that focuses on improving exercise tolerance, quality of life, and surgical outcomes for lung cancer patients. It includes exercise programs, breathing retraining, and self-management skills, which help patients become more active and manage symptoms like breathlessness, unlike traditional drug therapies.510111213
Research Team
Carolyn J. Presley, MD, MHS
Principal Investigator
Ohio State University Comprehensive Cancer Center
Eligibility Criteria
This trial is for adults aged 60 or older with advanced lung cancer (stage IIIA, IIIB, or IV non-small cell lung cancer or extensive stage small cell lung cancer). They must be able to understand and sign a consent form, have a certain level of physical function, and plan to receive treatment at the Ohio State University Comprehensive Cancer Center. Prisoners are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the ROAR-LCT intervention or standard of care for 12 weeks. The ROAR-LCT intervention includes weekly physical therapy visits and progressive muscle relaxation exercises.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of functional status and psychological symptoms.
Long-term follow-up
Participants are followed up for up to 24 months after the date of study enrollment to assess long-term outcomes.
Treatment Details
Interventions
- Exercise Intervention
- Physical Therapy
- Relaxation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
National Institute on Aging (NIA)
Collaborator